查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2108277

CRISPR和Cas基因編輯市場分析及預測（至2035年）：按類型、產品、服務、技術、組件、應用、流程、最終用戶和功能分類

CRISPR And Cas Genes Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, Process, End User, Functionality
出版日期: | 出版商: Global Insight Services | 英文 350 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

全球CRISPR和Cas基因市場預計將從2025年的51億美元成長到2035年的293億美元，複合年成長率（CAGR）為19.1%。 CRISPR和Cas基因市場正處於適度整合階段，領先的生物技術和生命科學公司專注於拓展其基因編輯平台、治療管線和研究工具的產品組合。市場成長的驅動力主要來自CRISPR技術在基因治療、藥物研發、功能基因體學和農業生物技術領域的日益普及。策略聯盟、產品創新、授權協議以及對臨床研究投入的增加，持續加劇市場競爭，並加速了基於CRISPR解決方案的商業化進程。例如，CRISPR Therapeutics公司於2025年5月公佈了其體內CRISPR基因編輯療法CTX310（靶向心血管疾病）的I期臨床試驗積極數據，這標誌著脂質奈米顆粒（LNP）介導的基因編輯在肝病治療領域取得了重大進展。

從技術細分領域來看，CRISPR/Cas9技術在2025年將主導CRISPR和Cas基因市場。這是因為它已成為研發、藥物發現和治療開發領域應用最廣泛的基因編輯技術。其高效的編輯效率、易於設計的引導RNA、成本效益以及在學術機構和商業實驗室中廣泛的檢驗記錄，都在加速其應用。 CRISPR/Cas9技術廣泛應用於功能基因體學、疾病建模、基因敲除研究及臨床前基因治療研究。除了豐富的商業化試劑盒、試劑和標準化工作流程外，生物技術和製藥公司的大量投資也持續鞏固其在生命科學研究和臨床創新整體的主導地位和廣泛應用。

市場區隔
類型 基因組編輯、基因工程、基因庫、CRISPR質體、CRISPR酶、CRISPR RNA等。
產品 試劑盒、試劑、細胞株、質體、載體等。
服務 gRNA設計、細胞株工程、篩檢服務等。
科技 CRISPR/Cas9、CRISPR/Cas12、CRISPR/Cas13 等。
成分 引導RNA、供體DNA模板、Cas核酸酶等。
目的 生物醫學研究、農業生物技術、工業生物技術、藥物開發、基因治療、診斷等領域。
過程 基因敲除、基因敲入、基因活化、基因抑制及其他
最終用戶 製藥公司、生技公司、學術和研究機構、受託研究機構等。
功能 標靶基因組編輯、功能基因體學、表觀基因編輯等。

按應用領域分類，基因治療領域預計將在預測期內實現最快成長。這主要得益於精準醫療的快速發展以及針對遺傳疾病、罕見疾病和癌症相關疾病的CRISPR療法的臨床開發不斷推進。基因編輯療法監管支持的擴大、生物技術投資的增加以及臨床試驗的增多，都在加速市場擴張。遞送技術的持續改進、編輯精度的提高以及脫靶效應的減少，正在提升CRISPR療法的安全性和有效性。隨著更多基因編輯療法走向商業化，預計在整個預測期內，對治療應用領域CRISPR技術的需求將顯著成長。

區域概覽

到2025年，北美將憑藉其成熟的生物技術生態系統、眾多領先的基因編輯公司以及在基因組學研究和精準醫療領域的大量投資，主導CRISPR和Cas基因市場。該地區將受益於政府機構、學術機構和私人投資者的廣泛資助，從而加速基於CRISPR的療法和研究工具的開發和商業化。美國將憑藉其先進的醫療保健基礎設施、眾多的臨床試驗機構、雄厚的研發資金以及眾多領先的生物技術和製藥公司，引領區域市場。加拿大將透過政府主導的舉措以及加強研究機構與產業參與者之間的合作，進一步推動區域成長。

預計亞太地區將在預測期內實現最快成長，這主要得益於生物技術研究的拓展、基因編輯技術投資的增加以及政府對基因組學和精準醫療日益成長的支持。中國、日本、韓國和印度等國家正透過增加研發投入、建立先進的基因組研究中心以及加強學術機構與生技公司之間的合作，迅速提升其在生命科學領域的實力。此外，該地區在農業生物技術、藥物研發和基因治療研究領域對CRISPR技術的應用也日益廣泛。醫療保健支出的成長、生物製藥生產的擴張以及創新支援政策預計將進一步加速亞太地區整體市場的成長。

主要趨勢和促進因素

利用CRISPR進行基因治療的臨床開發進展

隨著生技公司不斷擴大針對遺傳疾病、罕見疾病和癌症相關疾病的臨床試驗，CRISPR和Cas基因市場在基因編輯療法的臨床應用方面呈現強勁成長動能。 CRISPR系統的持續改進，包括編輯精度的提高、新型Cas變體的出現以及先進遞送技術的進步，正在增強治療的安全性和有效性。臨床研究、法規核准和商業化進程的不斷推進，正在加速CRISPR技術從實驗室轉向臨床應用的轉變。製藥公司為開發下一代基因編輯療法而增加投資並建立策略合作夥伴關係，也進一步推動了這一趨勢。

增加基因組研究和精準醫療的投資

全球對基因組學研究和精準醫療的投資不斷成長，是CRISPR和Cas基因市場的主要驅動力。各國政府、生技公司、製藥公司和研究機構正大幅增加對用於疾病治療、藥物研發和功能基因組學的創新基因編輯技術的投入。遺傳性疾病和癌症的日益普遍，以及對標靶治療需求的不斷成長，正在加速基於CRISPR的解決方案的普及應用。此外，不斷完善的研究基礎設施、優惠的資助計劃以及基因組編輯技術的進步，正在推動其在治療、農業和工業生物技術領域的廣泛商業化，從而加速市場成長。

目錄

第1章摘要整理

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制因素
  • 複合年均成長率分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章：細分市場分析

  • 市場規模及預測：依類型
    • 基因組編輯
    • 基因工程
    • 基因庫
    • CRISPR質體
    • CRISPR酶
    • CRISPR RNA
    • 其他
  • 市場規模及預測：依產品分類
    • 試劑盒和試劑
    • 細胞株
    • 質體
    • 向量
    • 其他
  • 市場規模及預測：依服務分類
    • gRNA設計
    • 細胞株工程
    • 篩檢服務
    • 其他
  • 市場規模及預測：依技術分類
    • CRISPR/Cas9
    • CRISPR/Cas12
    • CRISPR/Cas13
    • 其他
  • 市場規模及預測：依應用領域分類
    • 生物醫學研究
    • 農業生物技術
    • 工業生物技術
    • 藥物研發
    • 基因治療
    • 診斷
    • 其他
  • 市場規模及預測：依最終用戶分類
    • 製藥公司
    • 生技公司
    • 學術和研究機構
    • 受託研究機構
    • 其他
  • 市場規模及預測：依組件分類
    • 引導RNA
    • 供體DNA模板
    • Cas核酸酶
    • 其他
  • 市場規模及預測：依製程分類
    • 基因敲除
    • 基因敲入
    • 基因啟用設定
    • 基因抑制
    • 其他
  • 市場規模及預測：依功能分類
    • 標靶基因組編輯
    • 功能基因體學
    • 表觀基因編輯
    • 其他

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲國家
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 其他亞太國家
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲國家

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 定價和成本利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 大公司的策略

第8章：公司簡介

  • Editas Medicine
  • CRISPR Therapeutics
  • Intellia Therapeutics
  • Caribou Biosciences
  • Beam Therapeutics
  • Sangamo Therapeutics
  • Cellectis
  • Precision BioSciences
  • Horizon Discovery
  • Mammoth Biosciences
  • Synthego
  • Inscripta
  • Pairwise Plants
  • Locus Biosciences
  • eGenesis
  • Arbor BIoTechnologies
  • Crispr BIoTechnologies
  • GenEdit
  • Graphite Bio
  • Poseida Therapeutics

第9章 關於我們

簡介目錄
Product Code: GIS21360

The global CRISPR And Cas Genes Market is projected to grow from $5.1 billion in 2025 to $29.3 billion by 2035, at a compound annual growth rate (CAGR) of 19.1%. The CRISPR and Cas Genes Market is moderately consolidated, with leading biotechnology and life sciences companies focusing on expanding gene-editing platforms, therapeutic pipelines, and research tool portfolios. Market growth is driven by increasing adoption of CRISPR technologies in gene therapy, drug discovery, functional genomics, and agricultural biotechnology. Strategic collaborations, product innovations, licensing agreements, and rising investments in clinical research continue to strengthen the competitive landscape and accelerate commercialization of CRISPR-based solutions. For instance, in May 2025, CRISPR Therapeutics reported positive Phase 1 clinical data for CTX310, its in vivo CRISPR-based gene-editing therapy targeting cardiovascular disease, demonstrating a significant milestone in advancing lipid nanoparticle (LNP)-mediated gene editing for liver diseases.

Based on Technology, the CRISPR/Cas9 segment dominated the CRISPR and Cas Genes market in 2025 due to its established position as the most widely adopted gene-editing technology across research, drug discovery, and therapeutic development. Its high editing efficiency, ease of guide RNA design, cost-effectiveness, and extensive validation in academic and commercial laboratories have accelerated widespread adoption. CRISPR/Cas9 is extensively used in functional genomics, disease modeling, gene knockout studies, and preclinical gene therapy research. Strong availability of commercial kits, reagents, and standardized workflows, coupled with significant investments from biotechnology and pharmaceutical companies, continues to reinforce its leadership and broad application across life science research and clinical innovation.

Market Segmentation
TypeGenome Editing, Genetic Engineering, Gene Library, CRISPR Plasmid, CRISPR Enzyme, CRISPR RNA, Others
ProductKits and Reagents, Cell Lines, Plasmids, Vectors, Others
ServicesgRNA Design, Cell Line Engineering, Screening Services, Others
TechnologyCRISPR/Cas9, CRISPR/Cas12, CRISPR/Cas13, Others
ComponentGuide RNA, Donor DNA Templates, Cas Nucleases, Others
ApplicationBiomedical Research, Agricultural Biotechnology, Industrial Biotechnology, Drug Development, Gene Therapy, Diagnostics, Others
ProcessGene Knockout, Gene Knock-In, Gene Activation, Gene Repression, Others
End UserPharmaceutical Companies, Biotechnology Companies, Academic and Research Institutes, Contract Research Organizations, Others
FunctionalityTargeted Genome Editing, Functional Genomics, Epigenome Editing, Others

Based on Application, the Gene Therapy segment is projected to register the fastest growth during the forecast period, driven by the rapid advancement of precision medicine and increasing clinical development of CRISPR-based therapeutics targeting inherited, rare, and oncology-related diseases. Growing regulatory support for gene-editing therapies, rising investments in biotechnology, and expanding numbers of clinical trials are accelerating market expansion. Continuous improvements in delivery technologies, enhanced editing accuracy, and reduced off-target effects are improving the safety and efficacy of CRISPR-enabled treatments. As more gene-editing therapies progress toward commercialization, demand for CRISPR technologies in therapeutic applications is expected to increase significantly throughout the forecast period.

Geographical Overview

North America dominated the CRISPR and Cas Genes market in 2025, supported by its well-established biotechnology ecosystem, strong presence of leading gene-editing companies, and substantial investments in genomic research and precision medicine. The region benefits from extensive funding from government agencies, academic institutions, and private investors, accelerating the development and commercialization of CRISPR-based therapeutics and research tools. The United States leads the regional market owing to its advanced healthcare infrastructure, large number of clinical trials, favorable research funding, and presence of major biotechnology and pharmaceutical companies. Canada further strengthens regional growth through government-backed genomics initiatives and increasing collaborations between research organizations and industry participants.

Asia-Pacific is projected to register the fastest growth during the forecast period, driven by expanding biotechnology research, increasing investments in gene-editing technologies, and growing government support for genomics and precision medicine. Countries such as China, Japan, South Korea, and India are rapidly strengthening their life sciences capabilities through increased R&D funding, establishment of advanced genomic research centers, and rising collaborations between academia and biotechnology companies. The region is also witnessing growing adoption of CRISPR technologies in agricultural biotechnology, drug discovery, and gene therapy research. Rising healthcare expenditure, expanding biopharmaceutical manufacturing, and supportive innovation policies are expected to further accelerate market growth across Asia-Pacific.

Key Trends and Drivers

Increasing Clinical Advancement of CRISPR-Based Gene Therapies:

The CRISPR and Cas Genes market is witnessing a strong trend toward the clinical advancement of gene-editing therapies as biotechnology companies expand trials targeting genetic, rare, and oncology-related diseases. Continuous improvements in CRISPR systems, including enhanced editing precision, novel Cas variants, and advanced delivery technologies, are improving therapeutic safety and efficacy. The growing number of clinical studies, regulatory designations, and commercialization efforts is accelerating the transition of CRISPR from research laboratories to clinical applications. This trend is further supported by increasing investments from pharmaceutical companies and strategic collaborations aimed at developing next-generation gene-editing treatments.

Rising Investments in Genomics Research and Precision Medicine:

Growing global investments in genomics research and precision medicine are a major driver of the CRISPR and Cas Genes market. Governments, biotechnology companies, pharmaceutical firms, and research institutions are significantly increasing funding to develop innovative gene-editing technologies for disease treatment, drug discovery, and functional genomics. The rising prevalence of genetic disorders and cancer, coupled with increasing demand for targeted therapies, is accelerating the adoption of CRISPR-based solutions. In addition, expanding research infrastructure, favorable funding programs, and technological advancements in genome editing are enabling broader commercialization and accelerating market growth across therapeutic, agricultural, and industrial biotechnology applications.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Component
  • 2.8 Key Market Highlights by Process
  • 2.9 Key Market Highlights by Functionality

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Genome Editing
    • 4.1.2 Genetic Engineering
    • 4.1.3 Gene Library
    • 4.1.4 CRISPR Plasmid
    • 4.1.5 CRISPR Enzyme
    • 4.1.6 CRISPR RNA
    • 4.1.7 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Kits and Reagents
    • 4.2.2 Cell Lines
    • 4.2.3 Plasmids
    • 4.2.4 Vectors
    • 4.2.5 Others
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 gRNA Design
    • 4.3.2 Cell Line Engineering
    • 4.3.3 Screening Services
    • 4.3.4 Others
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 CRISPR/Cas9
    • 4.4.2 CRISPR/Cas12
    • 4.4.3 CRISPR/Cas13
    • 4.4.4 Others
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Biomedical Research
    • 4.5.2 Agricultural Biotechnology
    • 4.5.3 Industrial Biotechnology
    • 4.5.4 Drug Development
    • 4.5.5 Gene Therapy
    • 4.5.6 Diagnostics
    • 4.5.7 Others
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Pharmaceutical Companies
    • 4.6.2 Biotechnology Companies
    • 4.6.3 Academic and Research Institutes
    • 4.6.4 Contract Research Organizations
    • 4.6.5 Others
  • 4.7 Market Size & Forecast by Component (2020-2035)
    • 4.7.1 Guide RNA
    • 4.7.2 Donor DNA Templates
    • 4.7.3 Cas Nucleases
    • 4.7.4 Others
  • 4.8 Market Size & Forecast by Process (2020-2035)
    • 4.8.1 Gene Knockout
    • 4.8.2 Gene Knock-In
    • 4.8.3 Gene Activation
    • 4.8.4 Gene Repression
    • 4.8.5 Others
  • 4.9 Market Size & Forecast by Functionality (2020-2035)
    • 4.9.1 Targeted Genome Editing
    • 4.9.2 Functional Genomics
    • 4.9.3 Epigenome Editing
    • 4.9.4 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Component
      • 5.2.1.8 Process
      • 5.2.1.9 Functionality
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Component
      • 5.2.2.8 Process
      • 5.2.2.9 Functionality
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Component
      • 5.2.3.8 Process
      • 5.2.3.9 Functionality
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Component
      • 5.3.1.8 Process
      • 5.3.1.9 Functionality
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Component
      • 5.3.2.8 Process
      • 5.3.2.9 Functionality
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Component
      • 5.3.3.8 Process
      • 5.3.3.9 Functionality
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Component
      • 5.4.1.8 Process
      • 5.4.1.9 Functionality
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Component
      • 5.4.2.8 Process
      • 5.4.2.9 Functionality
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Component
      • 5.4.3.8 Process
      • 5.4.3.9 Functionality
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Component
      • 5.4.4.8 Process
      • 5.4.4.9 Functionality
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Component
      • 5.4.5.8 Process
      • 5.4.5.9 Functionality
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Component
      • 5.4.6.8 Process
      • 5.4.6.9 Functionality
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Component
      • 5.4.7.8 Process
      • 5.4.7.9 Functionality
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Component
      • 5.5.1.8 Process
      • 5.5.1.9 Functionality
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Component
      • 5.5.2.8 Process
      • 5.5.2.9 Functionality
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Component
      • 5.5.3.8 Process
      • 5.5.3.9 Functionality
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Component
      • 5.5.4.8 Process
      • 5.5.4.9 Functionality
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Component
      • 5.5.5.8 Process
      • 5.5.5.9 Functionality
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Component
      • 5.5.6.8 Process
      • 5.5.6.9 Functionality
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Component
      • 5.6.1.8 Process
      • 5.6.1.9 Functionality
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Component
      • 5.6.2.8 Process
      • 5.6.2.9 Functionality
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Component
      • 5.6.3.8 Process
      • 5.6.3.9 Functionality
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Component
      • 5.6.4.8 Process
      • 5.6.4.9 Functionality
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Component
      • 5.6.5.8 Process
      • 5.6.5.9 Functionality

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Editas Medicine
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 CRISPR Therapeutics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Intellia Therapeutics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Caribou Biosciences
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Beam Therapeutics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Sangamo Therapeutics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Cellectis
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Precision BioSciences
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Horizon Discovery
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Mammoth Biosciences
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Synthego
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Inscripta
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Pairwise Plants
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Locus Biosciences
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 eGenesis
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Arbor Biotechnologies
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Crispr Biotechnologies
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 GenEdit
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Graphite Bio
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Poseida Therapeutics
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us